Googled the new codes and came across various references, none specific to rates. Some will likely appear as reimbursement rates become public. One of the links contained the following:
"Radiation therapy can be delivered in two main ways, explained Dr. Hartsell, specifically teletherapy and brachytherapy. Radiation applied from the outside is called teletherapy, or long distance therapy, where the treatment beam has been generated at a distance using a linear accelerator or stereotactic radiosurgery. For example, intensity modulated radiation therapy (IMRT), such as is seen in 77300 is a type of teletherapy.
The second technique for delivery of radiation therapy is brachytherapy, or short distance therapy, where the radiation is placed either on or within the patient. Today, high-dose brachytherapy is primarily done remotely, meaning that the radiation oncologists, physicists, and therapists work at a distance from the radioactive materials being implanted on or in the patient, in a shielded area, saving the providers from excessive exposure to radiation.
Electronic brachytherapy, where the radiation source is placed in direct contact with the treatment site, gains two new category III codes to replace the existing category III code. New codes 0394T (High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed) and 0395T (High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed) will replace 0182T (High dose rate electronic brachytherapy, per fraction). The difference here is that 0394T is now available for radiation treatment to skin, such as for skin cancers. Code 0395T, the intracavitary treatment code, might be used for a woman with cervical cancer status post cervical removal, where electronic brachytherapy treatment would be administered directly to the vaginal cuff."
Just lurking, cymrules. I for one have not disappeared. I don't see a need to dramatize every step in the journey. I give you credit, however, for being honest in stating your short position unlike so many spreading FUD.
haschultz1, it's good to see your interest in GLUU. I highly value your opinion given your excellent due diligence work over at the HIMX MB.
Agreed the GLUU chart is awful. I'm sure you are aware the chart broke down after management provided disappointing (some say overly conservative) guidance for the present quarter. The stock could get a boost in the short-term from at least 2 upcoming events - the upcoming release of a Katy Perry/Jenner game and an anticipated beat of Q3 guidance. Question: Does your willingness to wait for a bullish cross indicate an expectation GLUU's stock price will languish despite the above catalysts? Best regards.
Your clinging to the theory of insider selling and the lack of insider buying as evidence of ICAD being a short candidate does not hold water.
Out of curiosity, I cross-checked the list of the best 2015 year-to-date stock performers from wwwDOTgreenandredmarketDOTcom to insider purchase/sale activity at wwwDOTinsidercowDOTcom. Out of the top 15 companies listed (including Sketchers, Sturm Ruger, Jet Blue and others), only 3 of the top 15 had any purchase activity whatsoever in the past year (often going back for many years). In 12 cases, the top performers had ZERO insider buying going back 3 years or more. Interesting huh?
Insider stock sales were extremely common in the time both preceding and during the sizeable run-up in the stock prices. Even Apple, without doubt one of the best performing companies ever, shows only 10 insider purchases for a measly 8000 shares since 3-24-08 compared to hundreds of sales totaling millions of shares. Never once did AAPL insiders jump to buy shares in defense of the stock price. Interesting again!
Insider buying MAY be a potentially valuable sign of a company's improving prospects. It is NOT, however, a prerequisite for strong price performance as the facts above show. The same goes for insider sales. Many top performers exhibit insider selling. It is not necessarily tied to some conspiracy theory as you suggest.
I bought some too, Micro, under $9.90. My expectations for KTCC have moderated over the years given the many disappointments with clients and their low margins. None the less, it appears KTCC has a reasonably good chance to grow revenues at a somewhat higher margin than has been typical. Not expecting a moonshot here but a decent return.
IMO the possibility of reimbursements being denied/materially reduced is the most likely reason for SP weakness. Yes the SP is up recently but not much relative to the significant fall since early May. Shorts' mention of management's share sales and failure to buy additional ones carry little weight with me. Statistically, many more sales than buys take place as managers monetize stock option shares. I also think shorts have overstayed their positions.
My case for investing in ICAD is based on the belief their diagnostic and therapeutic technology will be increasngly adopted despite financial incentives oncologists have to treat patients with repetitive radiation doses. Time will tell who is right. I'm confident longer-term returns will be very good.
The SP bounced off the 50 DMA of $3.66 today to end at $3.79. It will be interesting to see if the 50 provides support. The chart shows a series of higher lows since the early August bottom, an obvious bullish development.
The FINRA Reg SHO daily files shows a notable increase in recent total short volume. Since last Friday's 7427, the following 3 days have had short volume of 18189, 20909 and 32046 today. This might explain recent price weakness. FYI.
Today's low did not quite reach my limit order. With some good fortune I'll be picking up more shares soon. I'll have to content myself with my current holdings if ICAD finds support here.
Prospects sound very promising after listening to the earnings CC a while back and now the analyst conference. The uncertainty opened a wonderful buying opportunity IMO.
A few balance sheet, P&L and cash flow items have caught my attention:
ICAD has earned $.37 per share operating cash flow in the past 12 months. Not bad for a small high growth company.
ICAD's payoff of their long term debt (leaving $488K) will save $.15 per share in annualized pre-tax interest expense going forward, based on the last quarterly run rate. Great for EPS.
Balance sheet cash now exceeds their TOTAL liabilities. No problems with liquidity or credit quality here.
fitzy800, I'm wishing I bought more than the "prudent" slug I acquired back in the $3.20's. I'll be looking for any temporary pullback to right that wrong! Thank you for your insights, not only here but at the GLUU MB.
Per the 8-K Section 1.01 dated April 29, 2015 Tencent will be holding until at least October 2016:
Tencent and its Affiliates, including Red River, also agreed to a lock-up provision whereby they will not sell any of the Shares for a period of 18 months following the Initial Closing.